Wegovy (semaglutide) stays in your system for roughly five weeks after your last injection. The drug has a half-life of about seven days, meaning your body eliminates half of it each week. After five half-lives, the amount remaining is negligible, putting full clearance at approximately five weeks.
Why Wegovy Lasts So Long
Semaglutide was engineered to stick around. More than 99% of the drug binds to albumin, the most abundant protein in your blood. This albumin binding does two things: it shields semaglutide from being broken down by enzymes, and it prevents the kidneys from filtering it out quickly. The drug also absorbs slowly from the injection site under your skin, creating a gradual release into circulation.
This is why a single weekly shot maintains a steady level in your blood. By your second dose, you’ve already reached about 75% of the drug’s peak concentration. Full steady state, where levels plateau, takes four to five weeks of consecutive dosing.
Week-by-Week Elimination After Stopping
Here’s roughly what happens after your final injection, assuming you were on a stable dose:
- Week 1: About 50% of the drug remains. You’ll likely still feel appetite suppression and other effects.
- Week 2: About 25% remains.
- Week 3: About 12.5% remains. Effects start to noticeably fade for most people.
- Week 4: About 6% remains.
- Week 5: About 3% remains. This is generally considered functionally cleared.
These numbers are approximate. In practice, the drug’s appetite-suppressing effects tend to diminish before it’s fully out of your bloodstream, because the remaining concentration may drop below the threshold needed to produce a noticeable effect.
Does Your Dose Affect How Long It Stays?
Wegovy doses range from 0.25 mg during the initial escalation phase up to the 2.4 mg maintenance dose. The half-life itself, about 155 hours (roughly 6.5 days), stays consistent regardless of what dose you’re on. However, a higher dose means there’s more drug in your system to begin with, so the absolute amount lingering at each stage of elimination is greater. The timeline to near-zero clearance remains about five weeks either way.
Kidney and Liver Problems Don’t Change the Timeline
Because semaglutide is cleared primarily through protein metabolism rather than being filtered directly by the kidneys or processed heavily by the liver, impaired organ function doesn’t meaningfully change how long the drug stays in your system. FDA pharmacology reviews found no clinically relevant difference in drug levels across people with varying degrees of kidney disease, including those on dialysis, or across mild to severe liver impairment. You don’t need to worry about the drug accumulating if you have reduced kidney or liver function.
Practical Situations Where Clearance Matters
Planning a Pregnancy
The FDA-approved labeling for Wegovy recommends stopping the medication at least two months before trying to conceive. This buffer exceeds the five-week clearance window and provides an additional margin of safety, since animal studies raised concerns about fetal harm.
Before Surgery
One of Wegovy’s effects is slowing stomach emptying, which raised concerns about aspiration risk during anesthesia. Updated guidance from a multi-society panel of anesthesiologists now says most patients can continue their GLP-1 medication before elective surgery. The main exception is if you’re still in the dose escalation phase or experiencing active gastrointestinal side effects like nausea or vomiting. In those cases, elective surgery should be deferred until side effects have resolved. Your surgical team will give you specific instructions based on your situation.
Switching Medications
If you’re transitioning from Wegovy to another GLP-1 medication or a different treatment, the five-week clearance window matters for avoiding overlapping drug effects. Most prescribers will time the switch based on when your last Wegovy dose was given and how much is estimated to still be circulating.
What Happens as Wegovy Leaves Your System
Many people notice a gradual return of appetite in the weeks after stopping. The drug’s effect on hunger signals fades as blood levels decline, and this is often the first change people report. Weight regain is common after discontinuation. Clinical trials of semaglutide showed that participants regained roughly two-thirds of their lost weight within a year of stopping, largely because the biological drivers of appetite return to their pre-treatment baseline.
Blood sugar regulation also shifts. If semaglutide was helping manage insulin response, fasting blood sugar and post-meal glucose levels may start climbing within a few weeks of the last dose. Gastrointestinal side effects like nausea, on the other hand, resolve as the drug clears, which is welcome news for anyone who experienced them throughout treatment.